Gregory S Calip1, Joann G Elmore2, Denise M Boudreau3,4. 1. Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 South Wood Street MC 781, Chicago, IL, 60612, USA. gcalip@uic.edu. 2. Department of Medicine, University of Washington, Seattle, WA, USA. 3. Group Health Research Institute, Seattle, WA, USA. 4. Department of Pharmacy and Department of Epidemiology, University of Washington, Seattle, WA, USA.
Abstract
OBJECTIVE: Comorbidity among breast cancer survivors is prevalent, and adherence to medication management of comorbidities may be important for both chronic disease and cancer-related outcomes. Our objective was to determine characteristics associated with nonadherence to common chronic medications among breast cancer survivors. METHODS: We conducted a retrospective cohort study of 4216 women in an integrated care system diagnosed with early-stage breast cancer between 1990 and 2008 and alive without recurrence or second primary breast cancer in the second-year following diagnosis. Adherence to antihypertensives, oral diabetes medications, and statins was measured during the second-year post-breast cancer diagnosis using medication possession ratios (MPR). Nonadherence was defined as MPR <0.80. We estimated odds ratios (OR) and 95% confidence intervals (CI) for nonadherence to antihypertensives, oral diabetes medications, and statins by various characteristics using multivariable logistic regression. RESULTS: Among 2308 users of antihypertensives (n = 1779), diabetes medications (n = 499) and/or statins (n = 1072), 37% were nonadherent to antihypertensives; 75% were nonadherent to diabetes medications; 39% were nonadherent to statins. In adjusted models, younger age was associated with nonadherence to all three therapeutic classes. Certain cancer treatments were associated with nonadherence to antihypertensives (radiation: OR 1.21, 95% CI 1.01-1.47; endocrine therapy: OR 1.27, 95% CI 1.03-1.52) and diabetes medications (chemotherapy: OR 1.69, 95% CI 1.17-2.21). Less frequent primary care provider visits were associated with higher odds of nonadherence to antihypertensives (OR 1.70, 95% CI 1.19-2.22); and trends showed higher Charlson comorbidity scores associated with greater adherence to diabetes medications (P < 0.001) and statins (P = 0.032). CONCLUSIONS: Nonadherence to medications is high among breast cancer survivors, particularly diabetes medications, and is associated with cancer treatments and other patient characteristics. Additional research is warranted to understand the needs of cancer patients taking chronic medications and explore patient and provider factors influencing adherence.
OBJECTIVE: Comorbidity among breast cancer survivors is prevalent, and adherence to medication management of comorbidities may be important for both chronic disease and cancer-related outcomes. Our objective was to determine characteristics associated with nonadherence to common chronic medications among breast cancer survivors. METHODS: We conducted a retrospective cohort study of 4216 women in an integrated care system diagnosed with early-stage breast cancer between 1990 and 2008 and alive without recurrence or second primary breast cancer in the second-year following diagnosis. Adherence to antihypertensives, oral diabetes medications, and statins was measured during the second-year post-breast cancer diagnosis using medication possession ratios (MPR). Nonadherence was defined as MPR <0.80. We estimated odds ratios (OR) and 95% confidence intervals (CI) for nonadherence to antihypertensives, oral diabetes medications, and statins by various characteristics using multivariable logistic regression. RESULTS: Among 2308 users of antihypertensives (n = 1779), diabetes medications (n = 499) and/or statins (n = 1072), 37% were nonadherent to antihypertensives; 75% were nonadherent to diabetes medications; 39% were nonadherent to statins. In adjusted models, younger age was associated with nonadherence to all three therapeutic classes. Certain cancer treatments were associated with nonadherence to antihypertensives (radiation: OR 1.21, 95% CI 1.01-1.47; endocrine therapy: OR 1.27, 95% CI 1.03-1.52) and diabetes medications (chemotherapy: OR 1.69, 95% CI 1.17-2.21). Less frequent primary care provider visits were associated with higher odds of nonadherence to antihypertensives (OR 1.70, 95% CI 1.19-2.22); and trends showed higher Charlson comorbidity scores associated with greater adherence to diabetes medications (P < 0.001) and statins (P = 0.032). CONCLUSIONS: Nonadherence to medications is high among breast cancer survivors, particularly diabetes medications, and is associated with cancer treatments and other patient characteristics. Additional research is warranted to understand the needs of cancerpatients taking chronic medications and explore patient and provider factors influencing adherence.
Entities:
Keywords:
Breast cancer survivorship; Diabetes; Dyslipidemias; Hypertension; Medication adherence
Authors: Niteesh K Choudhry; William H Shrank; Raisa L Levin; Joy L Lee; Saira A Jan; M Alan Brookhart; Daniel H Solomon Journal: Am J Manag Care Date: 2009-07 Impact factor: 2.229
Authors: Craig J Currie; Mark Peyrot; Christopher Ll Morgan; Chris D Poole; Sara Jenkins-Jones; Richard R Rubin; Christopher M Burton; Marc Evans Journal: Diabetes Care Date: 2012-04-17 Impact factor: 19.112
Authors: Louise Foley; James Larkin; Richard Lombard-Vance; Andrew W Murphy; Lisa Hynes; Emer Galvin; Gerard J Molloy Journal: BMJ Open Date: 2021-09-02 Impact factor: 3.006
Authors: Alyce S Adams; Jeanne M Madden; Fang Zhang; Christine Y Lu; Dennis Ross-Degnan; Angelina Lee; Stephen B Soumerai; Dan Gilden; Neetu Chawla; Jennifer J Griggs Journal: Value Health Date: 2017-07-06 Impact factor: 5.725
Authors: Matthew P Banegas; Marc A Emerson; Alyce S Adams; Ninah S Achacoso; Neetu Chawla; Stacey Alexeeff; Laurel A Habel Journal: J Cancer Surviv Date: 2018-10-18 Impact factor: 4.442
Authors: Jennifer L Lund; Parul Gupta; Krutika B Amin; Ke Meng; Benjamin Y Urick; Katherine E Reeder-Hayes; Joel F Farley; Stephanie B Wheeler; Lisa Spees; Justin G Trogdon Journal: J Geriatr Oncol Date: 2020-05-15 Impact factor: 3.929
Authors: Leah L Zullig; Karen M Goldstein; Hayden B Bosworth; Sara M Andrews; Susanne Danus; George L Jackson; Dawn Provenzale; Morris Weinberger; Michael J Kelley; Corrine I Voils Journal: BMC Health Serv Res Date: 2018-03-09 Impact factor: 2.655
Authors: Anne Beiter Arreskov; Maria Å Olsen; Sandra Sinius Pouplier; Volkert Siersma; Christen L Andersen; Søren Friis; Niels de Fine Olivarius Journal: BMC Endocr Disord Date: 2019-06-11 Impact factor: 2.763
Authors: Leah L Zullig; Mohammad Shahsahebi; Benjamin Neely; Terry Hyslop; Renee A V Avecilla; Brittany M Griffin; Kacey Clayton-Stiglbauer; Theresa Coles; Lynda Owen; Bryce B Reeve; Kevin Shah; Rebecca A Shelby; Linda Sutton; Michaela A Dinan; S Yousuf Zafar; Nishant P Shah; Susan Dent; Kevin C Oeffinger Journal: BMC Fam Pract Date: 2021-11-18 Impact factor: 2.497
Authors: Justin G Trogdon; Krutika Amin; Parul Gupta; Benjamin Y Urick; Katherine E Reeder-Hayes; Joel F Farley; Stephanie B Wheeler; Lisa Spees; Jennifer L Lund Journal: PLoS One Date: 2021-11-29 Impact factor: 3.240